Abstract: The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.

Abstract: The present disclosure provides a compound of formula (I) targeting and degrading BCR-ABL protein and its use in the field of antitumor. The compound of formula (I) shows degradation and inhibitory effects on BCR-ABL target protein, which is mainly comprised of four moieties, wherein the first moiety (BCR-ABL-TKIs) is compound moiety with BCR-ABL tyrosine kinase inhibited activity; the second moiety (the LIN) is link units; the third moiety (the ULM) is a small molecule ligand for VHL or CRBN proteases with ubiquitination; and the four moiety (the group A) is carbonyl group that covalently binds to BCR-ABL-TKIs and LIN, and the LIN is further covalently bonded to ULM. A series of compounds designed and synthesized by the present disclosure shows extensive pharmacological effective, which function to degrade BCR-ABL protein and inhibit BCR-ABL effective, and can be utilized for treating relevant tumor.

Abstract: A light field image processing method is disclosed for removing occluding foreground and blurring uninterested objects, by differentiating objects located at different depths of field and objects belonging to distinct categories, to create see-through effects. In various embodiments, the image processing method may blur a background object behind a specified object of interest. The image processing method may also at least partially remove from the rendered image any occluding object that may prevent a viewer from viewing the object of interest. The image processing method may further blur areas of the rendered image that represent an object in the light field other than the object of interest. The method includes steps of constructing a light field weight function comprising a depth component and a semantic component, where the weight function assigns a ray in the light field with a weight; and conducting light field rendering using the weight function.

Abstract: The present disclosure relates to an in-situ temperature control platform, including an independent sample holder, a sample holder fixing cartridge, a customized sample stage and an anode contact pin. The independent sample holder includes a sample loading spot and a sample holder grip. The sample holder fixing cartridge includes a fixing cartridge body, the fixing cartridge body is provided with a sample holder slot, the bottom surface of the sample holder slot is provided with a heating element slot, and the sample holder slot is aligned with the sample loading spot. The bottom surface of the heating element slot is provided with a heating element fixing pinhole. The customized sample stage includes a sample stage body, the sample stage body is provided with a heating element support, and the heating element support is provided with a heating element.

Abstract: An optimized reconfiguration algorithm based on dynamic voltage and frequency scaling (DVFS) is provided, which mainly has the following contributions. The optimized reconfiguration algorithm based on DVFS proposes a DVFS-based reconfiguration method, which schedules user tasks according to a degree of parallelism (DOP) of the user tasks so as to reconfigure more parallel user tasks, thereby achieving higher reliability. The optimized reconfiguration algorithm based on DVFS proposes a K-means-based heuristic approximation algorithm, which minimizes the delay of the DVFS-based reconfiguration scheduling algorithm. The optimized reconfiguration algorithm based on DVFS proposes a K-means-based method, which reduces memory overhead caused by DVFS-based reconfiguration scheduling. The optimized reconfiguration algorithm based on DVFS improves the reliability of a field programmable gate array (FPGA) system and minimizes the area overhead of a hardware circuit.

Abstract: Disclosed are uses of NAD+ and/or NAD+ agonists and/or NAD+ inhibitors for preparing a preparation or a kit, and a combination preparation including T cells and NAD+ and/or NAD+ agonists and/or NAD+ inhibitors. The preparation or kit is used for regulating T cell activity, regulating the expression level of CD69 on the surface of T cells, and/or regulating the phosphorylation level in T cells, and/or treating diseases related to T cell activity.

Abstract: Provided are amino acid sequences capable of binding to and inhibiting a Cas protein's ability to bind to a nucleic acid molecule, thereby inhibiting the Cas protein's function in genome editing. Such Cas protein inhibitors, which can be comprised of a major coat protein (G8P), an extracellular region of the G8P (G8PEX), or a biological equivalent, are useful in improving the specificity of Cas protein-based genome editing procedures.

Abstract: Compositions and methods for detecting molecule-molecule interactions are provided. The methods employ a prokaryotic ubiquitin-like protein (Pup) and a Pup ligase that is coupled to one of the molecules. When the Pup ligase is brought to proximity to the other molecule by virtue of the molecule-molecule interaction, the Pup ligase can conjugate the Pup to a lysine residue on the other molecule. As such conjugation can be easily detected, this method allows easy identification of the molecule-molecule interaction.

Abstract: Disclosed is a use of an N-substituted pyridyl benzisoselazolone compound. The use is particularly a use in the preparation of a medicament for treating and/or preventing a disease caused by coronavirus. The present disclosure surprisingly found that the N-substituted pyridyl benzisoselazolone compound, such as ebselen, can significantly inhibit the activity of the main protease of a coronavirus and the intracellular replication capability of SARS-CoV-2, which can be used for treating a disease caused by coronavirus.

Abstract: An optimized reconfiguration algorithm based on dynamic voltage and frequency scaling (DVFS) is provided, which mainly has the following contributions. The optimized reconfiguration algorithm based on DVFS proposes a DVFS-based reconfiguration method, which schedules user tasks according to a degree of parallelism (DOP) of the user tasks so as to reconfigure more parallel user tasks, thereby achieving higher reliability. The optimized reconfiguration algorithm based on DVFS proposes a K-means-based heuristic approximation algorithm, which minimizes the delay of the DVFS-based reconfiguration scheduling algorithm. The optimized reconfiguration algorithm based on DVFS proposes a K-means-based method, which reduces memory overhead caused by DVFS-based reconfiguration scheduling. The optimized reconfiguration algorithm based on DVFS improves the reliability of a field programmable gate array (FPGA) system and minimizes the area overhead of a hardware circuit.

Abstract: The present invention provides a chimeric antigen receptor, which includes: an extracellular domain, a transmembrane domain, and an intracellular domain connected in sequence. The extracellular domain includes an antigen recognition region; the intracellular domain includes a costimulatory signaling region and a CD3? intracellular region that are connected in sequence, to form a costimulatory signaling region-CD3? intracellular region; and the costimulatory signaling region-CD3? intracellular region is a polypeptide formed by mutation of lysine in a wild-type costimulatory signaling region-CD3? intracellular region into arginine. The present invention provides a method for optimization and modification of CAR-T, in which all lysine sites in an intracellular segment of CAR are mutated into arginine, thereby blocking ubiquitination modification of the CAR after antigen challenge.

Abstract: A reaction control and mass spectrometry workstation for coupling an X-ray spectroscopic characterization instrument with an in-situ reaction cell, including a reactant gas composition control module and an online gas composition analyzing module. The workstation further involves a modification based on the original vacuum pipeline section. After the modification, the original vacuum pipeline section is connected to three customized gas ports, and the modification is characterized in that the vacuum manifold unit is additionally provided with a mass spectrometer sampling port, a sampling capillary, and control valves. The present disclosure has the following advantages. The sampling time delay can be ignored in the mass spectrometry, and the sampling is continuous real-time in-situ analysis with high time resolution.

Abstract: The present technology relates generally to compositions and methods of preventing or treating diseases associated with mutantleptin receptors, leptin deficiency or leptin dysfunction. The present technology also relates to administering the anti-leptin receptor antibodies in effective amounts to treat a subject suffering from, or predisposed to, a disease associated with mutant leptin receptors, obesity, leptin deficiency, leptin resistance, and/or hypoleptinemia.

Abstract: An efficient K-nearest neighbor search algorithm for three-dimensional (3D) lidar point cloud in unmanned driving and a use of the foregoing K-nearest neighbor search algorithm in a point cloud map matching process in the unmanned driving are provided. A novel data structure for fast K-nearest neighbor search is used, such that each voxel or sub-voxel includes a proper quantity of points to reduce redundant search. The novel K-nearest neighbor search algorithm is based on a double segmentation voxel structure (DSVS) and a field programmable gate array (FPGA). By means of the novel K-nearest neighbor search algorithm, nearest neighbors are searched for only in a neighboring expected area near a search point, thereby reducing search of redundant points. In addition, an optimized data transmission and access policy is used, which makes the algorithm more fit the characteristic of the FPGA.

Abstract: The present technology relates generally to compositions and methods of preventing or treating diseases associated with mutant Cx26, Cx32, and/or Cx30 hemichannels. The present technology also relates to administering the anti-Cx26 hemichannel antibodies in effective amounts to treat a subject suffering from, or predisposed to, ectodermal dysplasia 2, Clouston type (OMIM No. 129500), Keratitis-ichthyosis-deafness syndrome (KIDS; OMIM No. 148210), and/or type X Charcot-Marie-Tooth neuropathy (CMTXl; OMIM No. 302800).

Abstract: A method of detecting and recognizing faces using a light field camera array is provided. The method includes capturing multi-view color images using the light field camera array; obtaining a depth map; conducting light field rendering using a weight function comprising a depth component and a sematic component, where the weight function assigns a ray in the light field with a weight; and detecting and recognizing a face.

Abstract: A method of image processing for occlusion removal in images and videos captured by light field camera systems. The method comprises: capturing a plurality of camera views using a plurality of cameras; capturing a plurality of depth maps using a plurality of depth sensors; generating a depth map for each camera view; calculating a target view on a focal plane corresponding to a virtual camera; set a weighting function on the pixels on the camera views based on the depth map and a virtual distance; and blending the pixels in accordance with the weighting function to generate a refocused target view.

Abstract: Provided are fusion proteins and related molecules useful for conducting base editing with reduced or no off-target mutations. The fusion proteins may include a first fragment comprising a nucleobase deaminase or a catalytic domain thereof, a second fragment comprising a nucleobase deaminase inhibitory domain, and a protease cleavage site between the first fragment and the second fragment. Also provided are improved prime editing systems, including prime editing guide RNA with improved stability.

Abstract: Three-dimensional, living, self-regenerative structures of predetermined geometry comprising solidified print material comprising a biofilm of Bacillus subtilis comprise a TasA-R protein, wherein R is a recombinant, heterologous functional group, wherein the TasA-R provides a preferably tunable physiochemical property like viscosity, reactivity, affinity as a function of the R group.

Abstract: The present invention provides a fully human antibody specifically inhibiting Connexin 26, characterized in that it is a recombinant immunoglobulin having the structure of scFv-Fc, wherein scFv refers to a single-chain antibody comprising a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is SEQ ID NO: 1, the amino acid sequence of the light chain variable region is SEQ ID NO: 2, and Fc refers to constant region. The present invention uses the first 41-56 amino acid sequence of extracellular region of Connexin26 as an antigen, the sequence thereof is KEVWGDEQADFVCNTL. Through the biochemical analysis and immunofluorescence identification of the antibody obtained by single-chain antibody phage display library and screening technology, it was confirmed that the antibody provided by the present invention could specifically recognize Connexin 26 and inhibit its hemichannel activity.